May 23, 2014
Asahi Kasei Pharma Corp.
Asahi Kasei Pharma (Head office: Tokyo, Japan; President: Kazuyoshi Hori) has decided to construct a new manufacturing facility in Fuji, Shizuoka, Japan, for recombinant thrombomodulin alpha, the active ingredient of Recomodulin™ anticoagulant intravenous infusion 12800.
Developed by Asahi Kasei Pharma and marketed in Japan since 2008, Recomodulin™ is a thrombomodulin agent for the treatment of disseminated intravascular coagulation (DIC). It improves the symptoms of DIC with a new mechanism of controlling blood coagulation. DIC is known as a serious condition that often accompanies malignant tumors and infections.
Asahi Kasei Pharma currently produces the active ingredient of Recomodulin™ at its Fuji Pharmaceuticals Plant. The addition of the new manufacturing facility to the plant will enable the company to enhance its ability to assure reliable supply of the product.
Asahi Kasei Pharma will continue to further enhance its manufacturing capabilities for the stable provision of high-quality products for patients.
About Recomodulin™
Recomodulin™ is a thrombomodulin agent manufactured using genetic recombination technology. It acts as an anticoagulant by suppressing the activity and production of thrombin, a blood coagulation factor.
About DIC
DIC is a condition in which the blood coagulation system becomes overactive, leading to blockage of capillaries, ischemia and other damage to vascular endothelial cells, and organ damage, together with diminished consumption of hemostatic factors and aggravation of secondary fibrinolysis, resulting in severe bleeding. DIC frequently occurs as a complication of malignant tumors and infections. It has been reported that once DIC develops, prognosis worsens considerably.
Outline of the new manufacturing facility
| Location: | Fuji, Shizuoka, Japan | |
|---|---|---|
| Structure: | Three stories above ground | |
| Total floor area: | 4,500 m2 (scheduled) | |
| Groundbreaking: | April 2015 (scheduled) | |
| Completion: | June 2016 (scheduled) | |
| Start-up: | April 2017 (scheduled) |
Adobe Readeris required to view these PDF files.